Mutations in the gene for epsilon sarcoglycan are associated with a disorder of the central nervous system, the myoclonus-dystonia syndrome (MDS, OMIM 159900, DYT11). In contrast, mutations of other sarcoglycan family members lead to limb-girdle muscular dystrophies. The onset of MDS is usually in the first two decades of life. Dystonia, usually cervical and/or writer's cramp, occurs in many but not all patients. Rarely, dystonia may be the only phenotypic manifestation of the disease in an affected family member. Penetrance is incomplete and expressivity is variable both within and among families. Nearly all mutations published to date are associated with premature stop codons. Maternal imprinting has been shown to occur in both mice and humans and, as a result, reduced penetrance is seen when the mother passes on the mutant allele. When the mutant allele is inherited from the father, inactivation of the maternal allele due to imprinting leads to epsilon sarcoglycan deficiency. The similarities between DYT1 and DYT11 (e.g., variable expressivity, childhood onset, incomplete penetrance, writer's cramp presentation of adult-onset cases) suggests that there may be overlap in their molecular pathologies. Epsilon sarcoglycan can be detected in both neural (cerebellar cortex, striatum, cerebral cortex, thalamus, hippocampus) and non-neural (muscle, liver, kidney, heart) tissues from the embryo stage through adulthood. The developmental regulation of epsilon sarcoglycan expression is most striking in muscle with embryonic and early postnatal levels over ten times higher than those seen in adults. In adults, epsilon sarcoglycan transcript levels are several-fold higher in brain, particularly cerebellar cortex, than in muscle. As the next step towards understanding the role of this unique sarcoglycan in both neural function and the pathophysiology of dystonia, we propose to generate epsilon sarcoglycan knockout mice. In addition, antibodies to epsilon sarcoglycan will be produced for neuroanatomical and future functional studies of this unique membrane glycoprotein. We hypothesize that epsilon sarcoglycan co-localizes with GABA receptors opposite GABAergic terminals in the central nervous system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Research Grants (R03)
Project #
1R03NS050185-01A1
Application #
6967443
Study Section
Developmental Brain Disorders Study Section (DBD)
Program Officer
Tagle, Danilo A
Project Start
2005-06-15
Project End
2007-05-31
Budget Start
2005-06-15
Budget End
2006-05-31
Support Year
1
Fiscal Year
2005
Total Cost
$73,000
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Neurology
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Xiao, Jianfeng; Vemula, Satya R; Xue, Yi et al. (2017) Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome. Neurobiol Dis 98:52-65
Luciano, Angelo Y; Jinnah, H A; Pfeiffer, Ronald F et al. (2014) Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord 20:1423-6
Zhao, Y; Sharma, N; LeDoux, M S (2011) The DYT1 carrier state increases energy demand in the olivocerebellar network. Neuroscience 177:183-94
LeDoux, Mark S (2011) Animal models of dystonia: Lessons from a mutant rat. Neurobiol Dis 42:152-61
Zhao, Yu; DeCuypere, Michael; LeDoux, Mark S (2008) Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp Neurol 210:719-30
Zhao, Y; Xiao, J; Ueda, M et al. (2008) Glial elements contribute to stress-induced torsinA expression in the CNS and peripheral nervous system. Neuroscience 155:439-53
Yan, Jian; Jiao, Yan; Jiao, Feng et al. (2007) Effects of carbonic anhydrase VIII deficiency on cerebellar gene expression profiles in the wdl mouse. Neurosci Lett 413:196-201
LeDoux, Mark S; Xu, Lijing; Xiao, Jianfeng et al. (2006) Murine central and peripheral nervous system transcriptomes: comparative gene expression. Brain Res 1107:24-41